Iquum Gets FDA OK for Flu A/B Test; Eyes More Assays for Its Automated MDx System | GenomeWeb

By Ben Butkus

Clinical diagnostic test maker Iquum this week received US Food and Drug Administration clearance for its Liat Influenza A/B assay and fully automated and integrated Liat Analyzer.

Iguum said the real-time PCR-based test — its first 510(k) win — is designed to enable clinical labs to detect and differentiate influenza A and B in about 20 minutes, or about as fast as currently used immunoassays, but with the increased sensitivity afforded by nucleic acid testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.